Roche Hits Goal For Gazyva Expansion With Follicular Lymphoma Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales for Roche’s Rituxan follow-on Gazyva grew substantially in 2015 to $128m, but still pale compared to AbbVie/J&J’s Imbruvica, which is approved for three blood cancers and brought in more than $1bn.